ABVC Biopharma Inc
NASDAQ:ABVC
ABVC Biopharma Inc
NASDAQ:ABVC
Price:
1.5979
USD
-1.97%
Market Cap:
$41.2m
Balance Sheet
Balance Sheet Decomposition
ABVC Biopharma Inc
ABVC Biopharma Inc
Balance Sheet Decomposition is not available for
ABVC Biopharma Inc
ABVC Biopharma Inc
Balance Sheet
ABVC Biopharma Inc
ABVC Biopharma Inc
Currency: USD
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
4
|
6
|
0
|
0
|
0
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
4
|
6
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
3
|
0
|
1
|
1
|
2
|
1
|
1
|
1
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
1
|
2
|
1
|
1
|
1
|
|
| Total Current Assets |
3
|
1
|
1
|
6
|
10
|
3
|
2
|
2
|
|
| PP&E Net |
0
|
1
|
1
|
2
|
2
|
2
|
1
|
1
|
|
| PP&E Gross |
0
|
1
|
1
|
2
|
2
|
2
|
1
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
3
|
3
|
3
|
3
|
3
|
3
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Long-Term Investments |
0
|
3
|
3
|
1
|
1
|
1
|
3
|
2
|
|
| Other Long-Term Assets |
0
|
1
|
2
|
2
|
1
|
3
|
2
|
2
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
3
N/A
|
6
+125%
|
7
+17%
|
12
+68%
|
14
+18%
|
10
-28%
|
8
-21%
|
8
-3%
|
|
| Liabilities | |||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accrued Liabilities |
0
|
1
|
2
|
2
|
2
|
3
|
4
|
4
|
|
| Short-Term Debt |
0
|
1
|
2
|
2
|
2
|
2
|
1
|
1
|
|
| Current Portion of Long-Term Debt |
0
|
1
|
2
|
0
|
0
|
0
|
1
|
1
|
|
| Other Current Liabilities |
4
|
8
|
0
|
0
|
0
|
1
|
1
|
1
|
|
| Total Current Liabilities |
4
|
11
|
7
|
5
|
4
|
6
|
6
|
7
|
|
| Long-Term Debt |
0
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
|
| Other Liabilities |
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
|
| Total Liabilities |
4
N/A
|
12
+164%
|
7
-39%
|
8
+15%
|
5
-41%
|
7
+39%
|
6
-8%
|
6
+1%
|
|
| Equity | |||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
16
|
12
|
16
|
26
|
38
|
55
|
64
|
69
|
|
| Additional Paid In Capital |
14
|
15
|
28
|
41
|
58
|
68
|
74
|
79
|
|
| Treasury Stock |
0
|
9
|
9
|
9
|
9
|
9
|
9
|
9
|
|
| Other Equity |
0
|
1
|
3
|
3
|
2
|
1
|
1
|
0
|
|
| Total Equity |
2
N/A
|
6
-222%
|
0
+97%
|
3
N/A
|
9
+157%
|
3
-65%
|
2
-50%
|
1
-21%
|
|
| Total Liabilities & Equity |
3
N/A
|
6
+125%
|
7
+17%
|
12
+68%
|
14
+18%
|
10
-28%
|
8
-21%
|
8
-3%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
1
|
1
|
2
|
2
|
3
|
3
|
8
|
14
|
|
Switch to:
Switch to:
See Also
Discover More
